Breeze Meds vs Enhance MD: Which GLP-1 Provider Is Better?
A side-by-side comparison of Breeze Meds and Enhance MD covering pricing, scores, medication types, insurance, and more to help you decide.
Breeze Meds
#31 of 31Compounded GLP-1 provider focused on fast shipping and a no-fuss enrollment process.
Visit Breeze MedsEnhance MD
#8 of 31Affordable telehealth provider offering both compounded and brand-name GLP-1 medications with combination therapy options.
Visit Enhance MD| Feature | Breeze Meds | Enhance MD |
|---|---|---|
| Our Score | 7.3/10 | 8.3/10 |
| Starting Price | $189/mo | $115/mo |
| Medication Type | Compounded | Both |
| Insurance Accepted | No | No |
| Best For | Users who want a straightforward compounded GLP-1 program with fast shipping | Budget-conscious users interested in combination therapies |
| Ranking | #31 | #8 |
Pros & Cons Compared
Breeze Meds
Pros
- +Fast shipping
- +Simple enrollment
- +Competitive pricing
- +No fuss approach
Cons
- −Compounded only
- −Less comprehensive support
Enhance MD
Pros
- +$115/mo starting price with access to both brand-name and compounded — rare at this price point
- +Offers combination therapies (GLP-1 + B12, GLP-1 + NAD+) for patients wanting enhanced protocols
- +Quick asynchronous consultations — most patients approved within 24 hours without video calls
- +Flexible dosing: can start at lower doses than standard protocols for sensitive patients
Cons
- −Lighter clinical support than higher-priced platforms — check-ins are patient-initiated, not scheduled
- −No insurance billing and limited customer support hours (business days only, no weekends)
Our Verdict
Enhance MD edges out Breeze Meds with a score of 8.3/10 vs 7.3/10. If budget is your priority, Enhance MD starts at $115/mo compared to Breeze Meds's $189/mo. Enhance MD offers both brand-name and compounded medications, giving you more flexibility. Choose Breeze Meds if you want: users who want a straightforward compounded glp-1 program with fast shipping. Choose Enhance MD if you want: budget-conscious users interested in combination therapies.